Novartis Pharma Stein AG sold a building right on part of its industry area in Stein to Lonza AG. Lonza plans to construct a large-scale, commercial drug product fill & finish facility, which is expected to be completed in 2026. Lonza invests approx. CHF 500 million in its new facility.

Bär & Karrer acted as legal advisor to Novartis in this transaction. The team included Corrado Rampini and Kilian Müller (both Real Estate).

For further information please contact:

Media Relations, Eric Stupp

Tel: +41 58 261 50 00

Email: [email protected]